prednisone has been researched along with Neuralgia in 28 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Neuralgia: Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.
Excerpt | Relevance | Reference |
---|---|---|
"The effects of prednisone, oral acyclovir, and radiotherapy were compared with placebo in the prevention of post-herpetic neuralgia." | 9.07 | Prevention of post-herpetic neuralgia. Evaluation of treatment with oral prednisone, oral acyclovir, and radiotherapy. ( Allegra, F; Benoldi, D; Mirizzi, S; Zucchi, A, 1991) |
" The patients received PTX at the initiating dosage until complete clinical cure." | 6.71 | [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. ( Achirafi, A; de Carsalade, GY; Flageul, B, 2003) |
"Central poststroke pain is a neuropathic pain syndrome that can occur from pathology of the brain." | 5.43 | A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report. ( Batlle, L; Irwin, R; Mattie, R, 2016) |
"The effects of prednisone, oral acyclovir, and radiotherapy were compared with placebo in the prevention of post-herpetic neuralgia." | 5.07 | Prevention of post-herpetic neuralgia. Evaluation of treatment with oral prednisone, oral acyclovir, and radiotherapy. ( Allegra, F; Benoldi, D; Mirizzi, S; Zucchi, A, 1991) |
" We encountered severe autonomic neuropathy and cholestasis in a child receiving vincristine, after the introduction of piperacillin-tazobactam." | 3.78 | A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions? ( Andres, CR; Benz-de Bretagne, I; Gendrot, C; Jonville-Bera, AP; Jourdain, A; Le Guellec, C; Tarfaoui, N, 2012) |
"Eighty-eight eligible patients with Hodgkin lymphoma stage I and II (<3 nodal sites, no B symptoms, mediastinal bulk, or extranodal extension) enrolled between March 3, 2000, and December 9, 2008." | 2.77 | Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. ( Billett, AL; Billups, CA; Donaldson, SS; Friedmann, A; Howard, SC; Hudson, MM; Krasin, MJ; Kun, LE; Larsen, EC; Link, MP; Marcus, KJ; Metzger, ML; Tarbell, N; Weinstein, HJ; Wu, J; Yock, TI, 2012) |
" The patients received PTX at the initiating dosage until complete clinical cure." | 2.71 | [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. ( Achirafi, A; de Carsalade, GY; Flageul, B, 2003) |
"Central poststroke pain is a neuropathic pain syndrome that can occur from pathology of the brain." | 1.43 | A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report. ( Batlle, L; Irwin, R; Mattie, R, 2016) |
"Although occipital neuralgia is usually caused by degenerative arthropathy, nearly 20 other aetiologies may lead to this condition." | 1.42 | Idiopathic hypertrophic pachymeningitis presenting with occipital neuralgia. ( Auboire, L; Bienvenu, B; Boutemy, J; Busson, P; Constans, JM; Le Gallou, T, 2015) |
"A rare cause of trigeminal neuralgia is malignant lymphoma which spread along the trigeminal nerve." | 1.40 | [Malignant lymphoma in a perineural spreading along trigeminal nerve, which developed as trigeminal neuralgia]. ( Arakawa, T; Kobayashi, Y; Mano, T; Matsuo, K; Ozawa, H, 2014) |
"All patients had acute onset neuropathic pain, normal nerve conduction studies, and evidence of small-fiber dysfunction in quantitative sensory testing and skin biopsy." | 1.33 | Acute steroid responsive small-fiber sensory neuropathy: a new entity? ( Dabby, R; Gilad, R; Lampl, Y; Sadeh, M; Watemberg, N, 2006) |
"Herpes zoster is a common disease which is frequently followed by severe long-term pain--post-herpetic neuralgia." | 1.27 | Should we treat herpes zoster with corticosteroid agents? ( Dickinson, JA, 1986) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 15 (53.57) | 18.7374 |
1990's | 2 (7.14) | 18.2507 |
2000's | 4 (14.29) | 29.6817 |
2010's | 7 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Oerlemans, S | 1 |
Issa, DE | 1 |
van den Broek, EC | 1 |
Nijziel, MR | 1 |
Coebergh, JW | 1 |
Huijgens, PC | 1 |
Mols, F | 1 |
van de Poll-Franse, LV | 1 |
Mano, T | 1 |
Matsuo, K | 1 |
Kobayashi, Y | 2 |
Ozawa, H | 1 |
Arakawa, T | 1 |
Auboire, L | 1 |
Boutemy, J | 1 |
Constans, JM | 1 |
Le Gallou, T | 1 |
Busson, P | 1 |
Bienvenu, B | 1 |
Batlle, L | 1 |
Mattie, R | 1 |
Irwin, R | 1 |
Le Guellec, C | 1 |
Benz-de Bretagne, I | 1 |
Jonville-Bera, AP | 1 |
Tarfaoui, N | 1 |
Andres, CR | 1 |
Gendrot, C | 1 |
Jourdain, A | 1 |
Metzger, ML | 1 |
Weinstein, HJ | 1 |
Hudson, MM | 1 |
Billett, AL | 1 |
Larsen, EC | 1 |
Friedmann, A | 1 |
Howard, SC | 1 |
Donaldson, SS | 1 |
Krasin, MJ | 1 |
Kun, LE | 1 |
Marcus, KJ | 1 |
Yock, TI | 1 |
Tarbell, N | 1 |
Billups, CA | 1 |
Wu, J | 1 |
Link, MP | 1 |
Nizeica, V | 1 |
Collet, P | 1 |
Marotte, H | 1 |
Lagalla, G | 1 |
Logullo, F | 1 |
Di Bella, P | 1 |
Provinciali, L | 1 |
Ceravolo, MG | 1 |
ELLIOTT, FA | 1 |
de Carsalade, GY | 1 |
Achirafi, A | 1 |
Flageul, B | 1 |
Dabby, R | 1 |
Gilad, R | 1 |
Sadeh, M | 1 |
Lampl, Y | 1 |
Watemberg, N | 1 |
Gorson, KC | 1 |
Herrmann, DN | 1 |
Thiagarajan, R | 1 |
Brannagan, TH | 1 |
Chin, RL | 1 |
Kinsella, LJ | 1 |
Ropper, AH | 1 |
Clemmensen, OJ | 1 |
Andersen, KE | 1 |
Parkes, JD | 1 |
Calza, AM | 1 |
Schmied, E | 1 |
Harms, M | 1 |
Benoldi, D | 1 |
Mirizzi, S | 1 |
Zucchi, A | 1 |
Allegra, F | 1 |
Anderson, DJ | 1 |
Janoff, EN | 1 |
Diamond, S | 1 |
Dickinson, JA | 1 |
D'Elia, A | 1 |
Colella, C | 1 |
Contursi, R | 1 |
Pearce, J | 1 |
Kronschnabel, EF | 1 |
Saccabusi, E | 1 |
Burch, GE | 1 |
Giles, TD | 1 |
Reifenberg, E | 1 |
Fleischer, K | 1 |
Wieczorek, V | 1 |
Jung, H | 1 |
Leng-Lévy, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Risk-Adapted Therapy for Pediatric Hodgkin's Disease[NCT00145600] | Phase 2 | 296 participants (Actual) | Interventional | 2000-03-02 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Assess and compare the patient reported and parent proxy cognitive problems (child + teen) quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)
Intervention | units on a scale (Mean) |
---|---|
Patient Completion of 2 Cycles of Chemotherapy (T2) | 77.6 |
Parent Completion of 2 Cycles of Chemotherapy (T2) | 75.7 |
Patient Completion of 4 Cycles of Chemotherapy (T3) | 78.9 |
Parent Completion of 4 Cycles of Chemotherapy (T3) | 74.3 |
Patient 3-6 Months After the Completion of Therapy (T5) | 80.8 |
Parent 3-6 Months After the Completion of Therapy (T5) | 76.3 |
Assess and compare the patient reported and parent proxy communication quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)
Intervention | units on a scale (Mean) |
---|---|
Patient Completion of 2 Cycles of Chemotherapy (T2) | 78.3 |
Parent Completion of 2 Cycles of Chemotherapy (T2) | 73.6 |
Patient Completion of 4 Cycles of Chemotherapy (T3) | 80.6 |
Parent Completion of 4 Cycles of Chemotherapy (T3) | 74.9 |
Patient 3-6 Months After the Completion of Therapy (T5) | 83.7 |
Parent 3-6 Months After the Completion of Therapy (T5) | 83.1 |
Assess and compare the patient reported and parent proxy emotional quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).
Intervention | units on a scale (Mean) |
---|---|
Patient At Diagnosis (T1) | 68.4 |
Parent At Diagnosis (T1) | 62.3 |
Patient Completion of 2 Cycles of Chemotherapy (T2) | 70.7 |
Parent Completion of 2 Cycles of Chemotherapy (T2) | 64 |
Patient Completion of 4 Cycles of Chemotherapy (T3) | 74.1 |
Parent Completion of 4 Cycles of Chemotherapy (T3) | 65.7 |
Patient 3-6 Months After the Completion of Therapy (T5) | 78.5 |
Parent 3-6 Months After the Completion of Therapy (T5) | 77.1 |
Assess and compare the patient reported and parent proxy nausea quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)
Intervention | units on a scale (Mean) |
---|---|
Patient Completion of 2 Cycles of Chemotherapy (T2) | 60.7 |
Parent Completion of 2 Cycles of Chemotherapy (T2) | 58.6 |
Patient Completion of 4 Cycles of Chemotherapy (T3) | 59.7 |
Parent Completion of 4 Cycles of Chemotherapy (T3) | 57.7 |
Patient 3-6 Months After the Completion of Therapy (T5) | 75 |
Parent 3-6 Months After the Completion of Therapy (T5) | 78.9 |
Assess and compare the patient reported and parent proxy pain and hurt quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).
Intervention | units on a scale (Mean) |
---|---|
Patient Completion of 2 Cycles of Chemotherapy (T2) | 67.7 |
Parent Completion of 2 Cycles of Chemotherapy (T2) | 57.3 |
Patient Completion of 4 Cycles of Chemotherapy (T3) | 69.4 |
Parent Completion of 4 Cycles of Chemotherapy (T3) | 60.2 |
Patient 3-6 Months After the Completion of Therapy (T5) | 83.4 |
Parent 3-6 Months After the Completion of Therapy (T5) | 77 |
Assess and compare the patient reported and parent proxy Peds QL4 (composite) quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).
Intervention | units on a scale (Mean) |
---|---|
Patient At Diagnosis (T1) | 76.2 |
Parent At Diagnosis (T1) | 72.4 |
Patient Completion of 2 Cycles of Chemotherapy (T2) | 74.2 |
Parent Completion of 2 Cycles of Chemotherapy (T2) | 69.3 |
Patient Completion of 4 Cycles of Chemotherapy (T3) | 77 |
Parent Completion of 4 Cycles of Chemotherapy (T3) | 70.6 |
Patient 3-6 Months After the Completion of Therapy (T5) | 84 |
Parent 3-6 Months After the Completion of Therapy (T5) | 80.7 |
Assess and compare the patient reported and parent proxy PedsQL3 (composite) quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)
Intervention | units on a scale (Mean) |
---|---|
Patient Completion of 2 Cycles of Chemotherapy (T2) | 72.4 |
Parent Completion of 2 Cycles of Chemotherapy (T2) | 68.3 |
Patient Completion of 4 Cycles of Chemotherapy (T3) | 72.7 |
Parent Completion of 4 Cycles of Chemotherapy (T3) | 67.6 |
Patient 3-6 Months After the Completion of Therapy (T5) | 78.1 |
Parent 3-6 Months After the Completion of Therapy (T5) | 77.6 |
Assess and compare the patient reported and parent proxy perceived physical appearance quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)
Intervention | units on a scale (Mean) |
---|---|
Patient Completion of 2 Cycles of Chemotherapy (T2) | 77.5 |
Parent Completion of 2 Cycles of Chemotherapy (T2) | 71.9 |
Patient Completion of 4 Cycles of Chemotherapy (T3) | 77.6 |
Parent Completion of 4 Cycles of Chemotherapy (T3) | 71.2 |
Patient 3-6 Months After the Completion of Therapy (T5) | 78.4 |
Parent 3-6 Months After the Completion of Therapy (T5) | 80.5 |
Assess and compare the patient reported and parent proxy physical quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).
Intervention | units on a scale (Mean) |
---|---|
Patient At Diagnosis (T1) | 77.2 |
Parent At Diagnosis (T1) | 73.9 |
Patient Completion of 2 Cycles of Chemotherapy (T2) | 72.3 |
Parent Completion of 2 Cycles of Chemotherapy (T2) | 65.4 |
Patient Completion of 4 Cycles of Chemotherapy (T3) | 74.7 |
Parent Completion of 4 Cycles of Chemotherapy (T3) | 66.5 |
Patient 3-6 Months After the Completion of Therapy (T5) | 84.5 |
Parent 3-6 Months After the Completion of Therapy (T5) | 78.6 |
Assess and compare the patient reported and parent proxy procedural anxiety quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)
Intervention | units on a scale (Mean) |
---|---|
Patient Completion of 2 Cycles of Chemotherapy (T2) | 71.3 |
Parent Completion of 2 Cycles of Chemotherapy (T2) | 70.3 |
Patient Completion of 4 Cycles of Chemotherapy (T3) | 73.8 |
Parent Completion of 4 Cycles of Chemotherapy (T3) | 63.2 |
Patient 3-6 Months After the Completion of Therapy (T5) | 78.5 |
Parent 3-6 Months After the Completion of Therapy (T5) | 72.7 |
Assess and compare the patient reported and parent proxy psychosocial quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).
Intervention | units on a scale (Mean) |
---|---|
Patient At Diagnosis (T1) | 75.7 |
Parent At Diagnosis (T1) | 71.3 |
Patient Completion of 2 Cycles of Chemotherapy (T2) | 75.1 |
Parent Completion of 2 Cycles of Chemotherapy (T2) | 71.1 |
Patient Completion of 4 Cycles of Chemotherapy (T3) | 77.5 |
Parent Completion of 4 Cycles of Chemotherapy (T3) | 72.3 |
Patient 3-6 Months After the Completion of Therapy (T5) | 83.1 |
Parent 3-6 Months After the Completion of Therapy (T5) | 80.7 |
Assess and compare the patient reported and parent proxy school quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).
Intervention | units on a scale (Mean) |
---|---|
Patient At Diagnosis (T1) | 69.6 |
Parent At Diagnosis (T1) | 66.2 |
Patient Completion of 2 Cycles of Chemotherapy (T2) | 67.2 |
Parent Completion of 2 Cycles of Chemotherapy (T2) | 66.7 |
Patient Completion of 4 Cycles of Chemotherapy (T3) | 69 |
Parent Completion of 4 Cycles of Chemotherapy (T3) | 66.7 |
Patient 3-6 Months After the Completion of Therapy (T5) | 78.6 |
Parent 3-6 Months After the Completion of Therapy (T5) | 76.5 |
Assess and compare the patient reported and parent proxy social quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).
Intervention | units on a scale (Mean) |
---|---|
Patient At Diagnosis (T1) | 87.2 |
Parent At Diagnosis (T1) | 83 |
Patient Completion of 2 Cycles of Chemotherapy (T2) | 87.2 |
Parent Completion of 2 Cycles of Chemotherapy (T2) | 81.4 |
Patient Completion of 4 Cycles of Chemotherapy (T3) | 88.2 |
Parent Completion of 4 Cycles of Chemotherapy (T3) | 82.2 |
Patient 3-6 Months After the Completion of Therapy (T5) | 91.5 |
Parent 3-6 Months After the Completion of Therapy (T5) | 85.8 |
Assess and compare the patient reported and parent proxy treatment anxiety quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)
Intervention | units on a scale (Mean) |
---|---|
Patient Completion of 2 Cycles of Chemotherapy (T2) | 84.1 |
Parent Completion of 2 Cycles of Chemotherapy (T2) | 72.8 |
Patient Completion of 4 Cycles of Chemotherapy (T3) | 82.8 |
Parent Completion of 4 Cycles of Chemotherapy (T3) | 71.1 |
Patient 3-6 Months After the Completion of Therapy (T5) | 82.1 |
Parent 3-6 Months After the Completion of Therapy (T5) | 77.6 |
Assess and compare the patient reported and parent proxy worry quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)
Intervention | units on a scale (Mean) |
---|---|
Patient Completion of 2 Cycles of Chemotherapy (T2) | 64.5 |
Parent Completion of 2 Cycles of Chemotherapy (T2) | 64.5 |
Patient Completion of 4 Cycles of Chemotherapy (T3) | 64.7 |
Parent Completion of 4 Cycles of Chemotherapy (T3) | 64.7 |
Patient 3-6 Months After the Completion of Therapy (T5) | 67.1 |
Parent 3-6 Months After the Completion of Therapy (T5) | 68.6 |
Event-free survival (EFS) is based on the time from protocol enrollment to the occurrence of first event (relapse or progressive disease, subsequent malignancy, or death from any cause). Patients not experiencing an event are censored at their last follow-up date. Event-free Survival Probability will be estimated by Kaplan-Meier (KM) method with a 95% confidence interval calculated using the Greenwood's formula. (NCT00145600)
Timeframe: Median 6.4 year follow-up
Intervention | probability of 5 yr. event free survival (Number) |
---|---|
Favorable Risk | 0.886 |
Intermediate Risk | 0.844 |
Unfavorable Risk, Group 1 | 0.667 |
Unfavorable Risk, Group 2 | 0.793 |
Event-free survival (EFS) is based on the time from protocol enrollment to the occurrence of first event (relapse or progressive disease, subsequent malignancy, or death from any cause). Patients not experiencing an event are censored at their last follow-up date. Event-free Survival Probability will be estimated by Kaplan-Meier (KM) method with a 95% confidence interval calculated using the with Greenwood's formula. (NCT00145600)
Timeframe: 10-year follow-up after protocol enrollment
Intervention | probability 10 yr. event free survival (Number) |
---|---|
Favorable Risk | 0.874 |
Intermediate Risk | 0.844 |
Unfavorable Risk, Group 1 | 0.667 |
Unfavorable Risk, Group 2 | 0.785 |
6 trials available for prednisone and Neuralgia
Article | Year |
---|---|
Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Disease-Free Su | 2012 |
Influence of early high-dose steroid treatment on Bell's palsy evolution.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bell Palsy; Dose-Response Rela | 2002 |
[Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
Topics: Adolescent; Adult; Erythema Nodosum; Female; Follow-Up Studies; Glucocorticoids; Humans; Immunosuppr | 2003 |
ACTH versus prednisone and placebo in herpes zoster treatment.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Cosyntropin; Double-Blind Method; Female; Herpes | 1984 |
Prevention of post-herpetic neuralgia. Evaluation of treatment with oral prednisone, oral acyclovir, and radiotherapy.
Topics: Acute Disease; Acyclovir; Administration, Oral; Aged; Combined Modality Therapy; Female; Herpes Zost | 1991 |
[Controlled clinical trial a gastroprotective steroid (prednisone + xylamide)].
Topics: Amides; Arthritis, Rheumatoid; Asthma; Benzoates; Bronchitis; Chronic Disease; Drug Combinations; Ev | 1972 |
22 other studies available for prednisone and Neuralgia
Article | Year |
---|---|
Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
[Malignant lymphoma in a perineural spreading along trigeminal nerve, which developed as trigeminal neuralgia].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2014 |
Idiopathic hypertrophic pachymeningitis presenting with occipital neuralgia.
Topics: Cranial Nerve Diseases; Cyclophosphamide; Dura Mater; Headache; Humans; Immunosuppressive Agents; Ma | 2015 |
A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Thera | 2016 |
A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions?
Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; ATP Binding Cassette T | 2012 |
Bortezomib induced a phrenic palsy in a multiple myeloma patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acid | 2013 |
TREATMENT OF HERPES ZOSTER WITH HIGH DOSES OF PREDNISONE.
Topics: Geriatrics; Herpes Zoster; Herpes Zoster Ophthalmicus; Humans; Neuralgia; Prednisone; Prognosis | 1964 |
Acute steroid responsive small-fiber sensory neuropathy: a new entity?
Topics: Adolescent; Adult; Biopsy; Dermatologic Surgical Procedures; Female; Glucocorticoids; Humans; Immuno | 2006 |
Non-length dependent small fibre neuropathy/ganglionopathy.
Topics: Adult; Aged; Autonomic Nervous System; Biopsy; Cell Count; Extremities; Facial Pain; Female; Follow- | 2008 |
Diseases of the central nervous system. Relief of pain: headache, facial neuralgia, migraine, and phantom limb.
Topics: Analgesics; Aspirin; Carbamazepine; Ergotamines; Facial Neuralgia; Giant Cell Arteritis; Headache; H | 1975 |
Systemic corticosteroids do not prevent postherpetic neuralgia.
Topics: Female; Follow-Up Studies; Herpes Zoster; Humans; Male; Middle Aged; Neuralgia; Prednisone; Random A | 1992 |
Herpes zoster infection in a patient on methotrexate given prednisone to prevent post-herpetic neuralgia.
Topics: Aged; Female; Herpes Zoster; Humans; Methotrexate; Neuralgia; Prednisone; Virus Activation | 1987 |
Postherpetic neuralgia. Prevention and treatment.
Topics: Aged; Herpes Zoster; Humans; Middle Aged; Nerve Block; Neuralgia; Prednisone; Stellate Ganglion; Tri | 1987 |
Should we treat herpes zoster with corticosteroid agents?
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Carbamazepine; Child; Child, Preschool; Herpes Zos | 1986 |
Postherpetic neuralgia.
Topics: Herpes Zoster; Humans; Neuralgia; Prednisone | 1973 |
Orbital apex syndrome due to sinus infection.
Topics: Abscess; Anti-Bacterial Agents; Blepharoptosis; Blindness; Cellulitis; Conjunctiva; Cornea; Diagnosi | 1974 |
[Clinical trial of a drug with steroid activity combined with a gastroprotective substance].
Topics: Adult; Amides; Benzoates; Drug Combinations; Drug Tolerance; Gastric Juice; Glutamine; Humans; Infla | 1972 |
Cardiac causalgia.
Topics: Adult; Angina Pectoris; Arthritis; Body Temperature; Diagnosis, Differential; Electrocardiography; F | 1970 |
[The cervico-vertebral facial paresis].
Topics: Adult; Cervical Vertebrae; Facial Paralysis; Female; Humans; Male; Middle Aged; Neck; Neuralgia; Ost | 1967 |
[On the carotid pain. Giant cell arteritis and Hilger's syndrome].
Topics: Aged; Arteritis; Carotid Artery Diseases; Diagnosis, Differential; Female; Humans; Middle Aged; Migr | 1968 |
[On the clinical picture of the neuralgic amyotrophy (Syndrom of Parsonage and Turner)].
Topics: Adult; Blood Sedimentation; Cerebrospinal Fluid; Electromyography; Female; Humans; Male; Muscular At | 1965 |
[The antalgic and antirheumatic action of a neurotropic vitamin, aspirin and corticoid association].
Topics: Analgesics; Arthritis, Rheumatoid; Aspirin; Humans; Neuralgia; Prednisone; Vitamin B Complex | 1965 |